Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

Kalm Therapeutics (Kalm Tx) is pleased to announce the appointment of Dr. Tomoko Maeda-Chubachi, M.D., Ph.D., as our Chief ...

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...

This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

This summary of recent health news includes U.S. Senator Bernie Sanders advocating for cheaper Ozempic, new findings on ...

PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...

GSK’s oral treatment Jesduvroq increases erythropoietin ... Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, which ...

The Allergy & Clinical Immunology Society (ACIS) of Nigeria in association with Emerging Societies Program (ESP) is set to optimise allergy care at the first ever ...

Dr. Mahmoud Abdullah, Professor of Dermatology and Venereology at Ain ... Engineer Hassan Fahmi General Manager of GSK Egypt, spoke about the importance of introducing the "Shingrix" vaccine ...

An analysis of data from the phase 2 portion of the trial showed the primary efficacy objective had not been met. A study investigating GSK’s investigational herpes simplex virus (HSV) vaccine ...